CNBC
31 Aug 2026, 23:23 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Moderna announced promising results for an experimental melanoma vaccine developed with Merck. — Successful clinical results for a new mRNA application provide a material fundamental catalyst for revenue growth beyond COVID-19 vaccines.
+0.60The hedge fund Situational Awareness was forced to unwind large short positions against software stocks in late July. — The forced covering of leveraged short positions creates a short squeeze, driving prices up regardless of underlying fundamentals.
+0.50Super Micro Computer and Sandisk experienced price surges driven by booming demand for AI data center memory. — Strong demand for hardware components indicates continued capital expenditure in AI infrastructure.
+0.40Continue reading
6 related stories
Search tags
Salesforce and ServiceNow reported results showing AI integration and durability, challenging the 'SaaSpocalypse' narrative. — Evidence that AI is an additive tool rather than a disruptive replacement reduces systemic risk for the enterprise software sector.
+0.30The California Attorney General canceled a meeting with Paramount Skydance due to a perceived 'lack of good faith' in settlement talks. — Regulatory friction and poor relations with the AG create significant execution risk for the proposed acquisition.
-0.20Which stocks this story touches
Promising results for its experimental melanoma vaccine led to a 'miraculous' welcome.
Rebounded after a strong quarter undercut fears of a software collapse.
Rallied after demonstrating successful integration of AI into its business.
One of the month's top performers as cryptocurrencies rebounded.
Cramer highlighted its exceptional revenue growth and profitability during a sharp rebound.
Shares bounced back after fears of AI disruption proved overblown.
Joined the rebound as fears regarding AI models diminishing its research need were unfounded.
Explicitly preferred by Jim Cramer over Newmont.
Surged due to booming demand for AI data center memory.
Bounced back as deal roadblocks led investors to believe the company is not overpaying.
Mentioned as a partner in Moderna's promising vaccine results.
Benefited from a recovery in gold prices, though Cramer prefers a competitor.
[mutual] Moderna developed an experimental melanoma vaccine in partnership with Merck.
[a_to_b] Paramount has a proposed acquisition of Warner Bros. Discovery.
[mutual] Both companies are described as miners in the gold sector.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
55m ago
